Anwendungsgebiet
Paxneury is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6‑17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Paxneury must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
In anderen Ländern
Dieselben Wirkstoffe in anderen Registern, dieselbe Marke zuerst.
Nationale Einträge
Die nationalen Register, in denen dieses EU-Arzneimittel aufgeführt ist.
- Paxneury 1 MG Comprimidos de Liberacion Prolongada EfgSpanien · 1,148 mgIm Handel
- Paxneury 2 MG Comprimidos de Liberacion Prolongada EfgSpanien · 2,296 mgIm Handel
- Paxneury 3 MG Comprimidos de Liberacion Prolongada EfgSpanien · 3,444 mgIm Handel
- Paxneury 4 MG Comprimidos de Liberacion Prolongada EfgSpanien · 4,592 mgIm Handel